EssilorLuxottica will acquire Optegra, an integrated ophthalmology provider that operates eye hospitals and clinics in five key European markets: the United Kingdom, Czech Republic, Poland, Slovakia and the Netherlands.
According to a press release, the acquisition represents “a significant milestone in EssilorLuxottica’s med-tech strategy”.
We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with healthcare potential, and diagnostic capabilities…
The Optegra group, under the Optegra, Lexum and Iris brands, and owned by MidEuropa, operates a network of over 70 eye hospitals and diagnostic facilities across Europe, offering medically necessary ophthalmic treatments and elective vision correction procedures supported by artificial intelligence (AI) in pre- and post-op stages. These include cataract surgery, age-related macular degeneration and glaucoma treatments, refractive lens replacement and laser eye surgery, serving both publicly reimbursed and private-pay patients.
In a joint statement, Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica said the acquisition of the Optegra group would enable EssilorLuxottica to step “into a new frontier – one where comprehensive eye care, advanced diagnostics, therapeutic interventions and surgical treatments come together in one seamless platform”.
“We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with healthcare potential, and diagnostic capabilities that will be able to detect conditions ranging from neurodegenerative diseases to cardiovascular dysfunction.
“Optegra and its experienced doctors will bring new medical capabilities to our Group, enabling us to address patients’ needs with the most advanced vision care technologies and treatments in one trusted system that will anchor our med-tech aspirations. Powered by our growing AI and big data capabilities, we will be able to broaden our impact and deliver the most personalized and seamless patient journey,”
The transaction is expected to close later in 2025 pending regulatory approvals and other customary closing conditions.
